WO2013011402A1 - Modulateurs de gpr 119 - Google Patents
Modulateurs de gpr 119 Download PDFInfo
- Publication number
- WO2013011402A1 WO2013011402A1 PCT/IB2012/053381 IB2012053381W WO2013011402A1 WO 2013011402 A1 WO2013011402 A1 WO 2013011402A1 IB 2012053381 W IB2012053381 W IB 2012053381W WO 2013011402 A1 WO2013011402 A1 WO 2013011402A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diabetes
- oxy
- disease
- carboxylate
- composition
- Prior art date
Links
- KFDZKKDCLWHKQR-YZVOILCLSA-N CC(C)(C)OC(N(CC[C@@H]1OC([C@@](C(F)(F)F)(c2ccccc2)OC)=O)C[C@@H]1F)=O Chemical compound CC(C)(C)OC(N(CC[C@@H]1OC([C@@](C(F)(F)F)(c2ccccc2)OC)=O)C[C@@H]1F)=O KFDZKKDCLWHKQR-YZVOILCLSA-N 0.000 description 1
- YMZLTWMYMNFKOU-RDJZCZTQSA-N CC1(CC1)OC(N(CC[C@@H]1Oc2ncnc(Oc3cccnc3C)c2C)C[C@@H]1F)=O Chemical compound CC1(CC1)OC(N(CC[C@@H]1Oc2ncnc(Oc3cccnc3C)c2C)C[C@@H]1F)=O YMZLTWMYMNFKOU-RDJZCZTQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Such acids are for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxy-benzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid, and sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid.
- Such salts can exist in either a hydrated or substantially anhydrous form. In general, the acid addition salts of these compounds are soluble in water and various hydrophilic organic solvents.
- the composition further includes at least one additional pharmaceutical agent selected from the group consisting of an anti-obesity agent and an anti-diabetic agent.
- Example anti-obesity agents include dirlotapide, mitratapide, implitapide, R56918 (CAS No. 403987), CAS No. 913541-47-6, lorcaserin, cetilistat, PYY3-36, naltrexone, oleoyl-estrone, obinepitide, pramlintide, tesofensine, leptin, liraglutide, bromocriptine, orlistat, exenatide, AOD-9604 (CAS No.
- the compounds may be used to treat neurological disorders such as Alzheimer's disease, schizophrenia, and impaired cognition.
- the compounds will also be beneficial in gastrointestinal illnesses such as inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, etc.
- the compounds may also be used to stimulate weight loss in obese patients, especially those afflicted with diabetes.
- the present invention further provides a method for preventing or ameliorating the symptoms of any of the diseases or disorders described above in a subject in need thereof, which method comprises administering to a subject a therapeutically effective amount of a compound of the present invention.
- Further aspects of the invention include the preparation of medicaments for the treating diabetes and its related co-morbidities.
- the compounds need to be administered in a quantity sufficient to modulate activation of the G-protein- coupled receptor GPR1 19. This amount can vary depending upon the particular disease/condition being treated, the severity of the patient's disease/condition, the patient, the particular compound being administered, the route of administration, and the presence of other underlying disease states within the patient, etc.
- the compounds When administered systemically, the compounds typically exhibit their effect at a dosage range of from about 0.1 mg/kg/day to about 100 mg/kg/day for any of the diseases or conditions listed above. Repetitive daily administration may be desirable and will vary according to the conditions outlined above.
- a 1 L flask was charged with titanium methoxide (100 g), cyclohexanol (232 g), and toluene (461 ml_). The flask was equipped with a Dean-Stark trap and condenser. The mixture was heated at 140 degrees Celsius until the methanol was removed. The toluene was removed at 180 degrees Celsius. More toluene was added and this process was repeated twice. After all the toluene was removed the flask was dried under high vacuum. Diethyl ether (580 mL) was added to the flask to prepare a 1 M solution in diethyl ether.
- the aqueous layer was extracted twice with ethyl acetate, and all the organic layers were combined and washed sequentially with saturated aqueous sodium bicarbonate and brine and then dried over magnesium sulfate. The mixture was filtered, and the filtrate was
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12738619.1A EP2731944A1 (fr) | 2011-07-15 | 2012-07-03 | Modulateurs de gpr 119 |
JP2014520751A JP2014520879A (ja) | 2011-07-15 | 2012-07-03 | Gpr119調節因子 |
CA2841757A CA2841757A1 (fr) | 2011-07-15 | 2012-07-03 | Modulateurs de gpr 119 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161508250P | 2011-07-15 | 2011-07-15 | |
US61/508,250 | 2011-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013011402A1 true WO2013011402A1 (fr) | 2013-01-24 |
Family
ID=46579270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/053381 WO2013011402A1 (fr) | 2011-07-15 | 2012-07-03 | Modulateurs de gpr 119 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2731944A1 (fr) |
JP (1) | JP2014520879A (fr) |
CA (1) | CA2841757A1 (fr) |
WO (1) | WO2013011402A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014011926A1 (fr) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique |
WO2015092610A1 (fr) | 2013-12-20 | 2015-06-25 | Pfizer Limited | Inhibiteurs de kinase apparentés à la n-acylpipéridine éther tropomyosine |
WO2016153949A1 (fr) * | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Composés 5-deutéro-thiazolidine-2,4-dione et procédés de traitement de troubles médicaux les utilisant |
US9833445B2 (en) | 2013-03-14 | 2017-12-05 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
WO2018049324A1 (fr) * | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Composés monocycliques utiles comme modulateurs de gpr120 |
US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US10576071B2 (en) | 2007-09-26 | 2020-03-03 | Poxel Sa | Deuterium-enriched pioglitazone |
US10865201B2 (en) | 2016-09-12 | 2020-12-15 | Valo Health, Inc. | Bicyclic compounds useful as GPR120 modulators |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
CN115385849A (zh) * | 2022-09-14 | 2022-11-25 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003072197A1 (fr) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Inhibiteurs de l'acetyl-coa-carboxylase |
US6818658B2 (en) | 2001-02-28 | 2004-11-16 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
US20050267100A1 (en) | 2004-05-25 | 2005-12-01 | Pfizer Inc | Tetraazabenzo[e]azulene derivatives and analogs thereof |
WO2005116014A1 (fr) | 2004-05-12 | 2005-12-08 | Pfizer Products Inc. | Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv |
WO2005121121A2 (fr) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes |
US20060178501A1 (en) | 2005-02-04 | 2006-08-10 | Pfizer Inc | PYY agonists and use thereof |
WO2007122482A1 (fr) | 2006-04-20 | 2007-11-01 | Pfizer Products Inc. | Composés phényle amido-hétérocycliques fusionnés pour la prévention et le traitement de maladies à médiation par glucokinase |
WO2008065508A1 (fr) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Inhibiteurs de la spirocétoneacétyl-coa carboxylase |
WO2009016462A2 (fr) | 2007-08-02 | 2009-02-05 | Pfizer Products Inc. | Bicyclolactames substitués |
WO2009105717A1 (fr) | 2008-02-22 | 2009-08-27 | Irm Llc | Composés et compositions comme modulateurs d'activité de gpr119 |
WO2009144555A1 (fr) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase |
WO2009144554A1 (fr) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase |
WO2010013161A1 (fr) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Hétéroaryles fluorés |
WO2010023594A1 (fr) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol |
WO2010086820A1 (fr) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle |
WO2010103438A1 (fr) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Indazole amides substitués |
WO2010103437A1 (fr) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase |
WO2010106457A2 (fr) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3,3.1]nonanes |
WO2010128425A1 (fr) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Modulateurs de gpr119 |
WO2010128414A1 (fr) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Modulateurs du gpr119 |
WO2010140092A1 (fr) | 2009-06-05 | 2010-12-09 | Pfizer Inc. | Derives de l-(piperidin-4-yl)-pyrazole utilises en tant que modulateurs du gpr 119 |
WO2011005611A1 (fr) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de la neuromédine u et leurs utilisations |
-
2012
- 2012-07-03 EP EP12738619.1A patent/EP2731944A1/fr not_active Withdrawn
- 2012-07-03 WO PCT/IB2012/053381 patent/WO2013011402A1/fr active Application Filing
- 2012-07-03 JP JP2014520751A patent/JP2014520879A/ja active Pending
- 2012-07-03 CA CA2841757A patent/CA2841757A1/fr not_active Abandoned
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6818658B2 (en) | 2001-02-28 | 2004-11-16 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
WO2003072197A1 (fr) | 2002-02-27 | 2003-09-04 | Pfizer Products Inc. | Inhibiteurs de l'acetyl-coa-carboxylase |
WO2005116014A1 (fr) | 2004-05-12 | 2005-12-08 | Pfizer Products Inc. | Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv |
US20050267100A1 (en) | 2004-05-25 | 2005-12-01 | Pfizer Inc | Tetraazabenzo[e]azulene derivatives and analogs thereof |
WO2005116034A1 (fr) | 2004-05-25 | 2005-12-08 | Pfizer Products Inc. | Derives de tetraazabenzo[e]azulene et analogues de ceux-ci |
WO2005121121A2 (fr) | 2004-06-04 | 2005-12-22 | Arena Pharmaceuticals, Inc. | Derives d'aryle et d'heteroaryle substitues tenant lieu de modulateurs du metabolisme et prevention et traitement de troubles associes |
US20060178501A1 (en) | 2005-02-04 | 2006-08-10 | Pfizer Inc | PYY agonists and use thereof |
WO2007122482A1 (fr) | 2006-04-20 | 2007-11-01 | Pfizer Products Inc. | Composés phényle amido-hétérocycliques fusionnés pour la prévention et le traitement de maladies à médiation par glucokinase |
WO2008065508A1 (fr) | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Inhibiteurs de la spirocétoneacétyl-coa carboxylase |
WO2009016462A2 (fr) | 2007-08-02 | 2009-02-05 | Pfizer Products Inc. | Bicyclolactames substitués |
WO2009105717A1 (fr) | 2008-02-22 | 2009-08-27 | Irm Llc | Composés et compositions comme modulateurs d'activité de gpr119 |
WO2009144555A1 (fr) | 2008-05-28 | 2009-12-03 | Pfizer Inc. | Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase |
WO2009144554A1 (fr) | 2008-05-28 | 2009-12-03 | Pfizer, Inc. | Inhibiteurs de la pyrazolospirocétone acétl-coa carboxylase |
WO2010013161A1 (fr) | 2008-07-29 | 2010-02-04 | Pfizer Inc. | Hétéroaryles fluorés |
WO2010023594A1 (fr) | 2008-08-28 | 2010-03-04 | Pfizer Inc. | Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol |
WO2010086820A1 (fr) | 2009-02-02 | 2010-08-05 | Pfizer Inc. | Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle |
WO2010103438A1 (fr) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Indazole amides substitués |
WO2010103437A1 (fr) | 2009-03-11 | 2010-09-16 | Pfizer Inc. | Dérivés de benzofuranyle utilisés comme inhibiteurs de la glucokinase |
WO2010106457A2 (fr) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3,3.1]nonanes |
WO2010128425A1 (fr) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Modulateurs de gpr119 |
WO2010128414A1 (fr) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Modulateurs du gpr119 |
WO2010140092A1 (fr) | 2009-06-05 | 2010-12-09 | Pfizer Inc. | Derives de l-(piperidin-4-yl)-pyrazole utilises en tant que modulateurs du gpr 119 |
WO2011005611A1 (fr) | 2009-07-09 | 2011-01-13 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de la neuromédine u et leurs utilisations |
Non-Patent Citations (13)
Title |
---|
"Reminqton''s Pharmaceutical Sciences", UNIVERSITY OF THE SCIENCES IN PHILADELPHIA |
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, 2011, pages 1306 - 1309 |
CARPINO, P.A.; GOODWIN, B., EXPERT OPIN. THER., vol. 20, no. 12, 2010, pages 1627 - 51 |
DALE, J. A.; MOSHER, H. S., J. AM. CHEM. SOC., vol. 95, 1973, pages 512 - 519 |
DEMONG, D.E. ET AL., ANNUAL REPORTS IN MEDICINAL CHEMISTRY, vol. 43, 2008, pages 119 - 137 |
E.C. CHAO ET AL., NATURE REVIEWS DRUG DISCOVERY, vol. 9, July 2010 (2010-07-01), pages 551 - 559 |
JONES, R.M. ET AL., MEDICINAL CHEMISTRY, vol. 44, 2009, pages 149 - 170 |
KHARITONENKOV, A. ET AL., CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 10, no. 4, 2009, pages 359 - 364 |
MEDINA, J.C., ANNUAL REPORTS IN MEDICINAL CHEMISTRY, vol. 43, 2008, pages 75 - 85 |
T. W. GREENE: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS |
VINCENT MASCITTI ET AL: "Design and evaluation of a 2-(2,3,6-trifluorophenyl)acetamide derivative as an agonist of the GPR119 receptor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 21, no. 5, 20 January 2011 (2011-01-20), pages 1306 - 1309, XP028144469, ISSN: 0960-894X, [retrieved on 20110125], DOI: 10.1016/J.BMCL.2011.01.088 * |
ZHANG, S. ET AL., DRUG DISCOVERY TODAY, vol. 12, no. 9/10, 2007, pages 373 - 381 |
ZHONG, M., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 10, no. 4, 2010, pages 386 - 396 |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10940143B2 (en) | 2007-09-26 | 2021-03-09 | Poxel Sa | Deuterium-enriched pioglitazone |
US11918567B2 (en) | 2007-09-26 | 2024-03-05 | Poxel Sa | Deuterium-enriched pioglitazone |
US10576071B2 (en) | 2007-09-26 | 2020-03-03 | Poxel Sa | Deuterium-enriched pioglitazone |
WO2014011926A1 (fr) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique |
US11918569B2 (en) | 2013-03-14 | 2024-03-05 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US9833445B2 (en) | 2013-03-14 | 2017-12-05 | Deuterx, Llc | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US10265305B2 (en) | 2013-03-14 | 2019-04-23 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
US11123336B2 (en) | 2013-03-14 | 2021-09-21 | Poxel Sa | 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same |
WO2015092610A1 (fr) | 2013-12-20 | 2015-06-25 | Pfizer Limited | Inhibiteurs de kinase apparentés à la n-acylpipéridine éther tropomyosine |
US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
US11141411B2 (en) | 2014-01-15 | 2021-10-12 | Poxel Sa | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
WO2016153949A1 (fr) * | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Composés 5-deutéro-thiazolidine-2,4-dione et procédés de traitement de troubles médicaux les utilisant |
US10865201B2 (en) | 2016-09-12 | 2020-12-15 | Valo Health, Inc. | Bicyclic compounds useful as GPR120 modulators |
US10800773B2 (en) | 2016-09-12 | 2020-10-13 | Integral Health, Inc. | Monocyclic compounds useful as GPR120 modulators |
US11548886B2 (en) | 2016-09-12 | 2023-01-10 | Valo Health, Inc. | Monocyclic compounds useful as GPR120 modulators |
US11919891B2 (en) | 2016-09-12 | 2024-03-05 | Valo Health, Inc. | Bicyclic compounds useful as GPR120 modulators |
WO2018049324A1 (fr) * | 2016-09-12 | 2018-03-15 | Numerate, Inc. | Composés monocycliques utiles comme modulateurs de gpr120 |
US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
CN115385849A (zh) * | 2022-09-14 | 2022-11-25 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
CN115385849B (zh) * | 2022-09-14 | 2024-01-26 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2841757A1 (fr) | 2013-01-24 |
EP2731944A1 (fr) | 2014-05-21 |
JP2014520879A (ja) | 2014-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120095028A1 (en) | 3-oxa-7-azabicyclo[3.3.1]nonanes | |
WO2013011402A1 (fr) | Modulateurs de gpr 119 | |
US10662171B2 (en) | Antidiabetic bicyclic compounds | |
US20110020460A1 (en) | Gpr 119 modulators | |
US20120052130A1 (en) | Gpr 119 modulators | |
WO2010128425A1 (fr) | Modulateurs de gpr119 | |
EP3055300B1 (fr) | Antagonistes de récepteur ep3 de prostaglandine | |
US20100285145A1 (en) | Gpr 119 modulators | |
JP2015506355A (ja) | 新規アゼチジン誘導体、医薬組成物およびそれらの使用 | |
TWI433843B (zh) | Gpr119調節子 | |
US20160176851A1 (en) | Antagonists of prostaglandin ep3 receptor | |
US20120295845A1 (en) | Imidazo-pyrazoles as gpr119 inhibitors | |
US20130072427A1 (en) | Gpr 119 modulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12738619 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012738619 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2841757 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014520751 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |